MHRA Guidance: MHRA QPPV and PSMF Guidance for UK Market Authorisations

Navigating New Horizons: MHRA QPPV and PSMF Guidance

The MHRA QPPV and PSMF guidance published by the UK regulator mandates UK marketing authorisation holder pharmacovigilance teams to have a qualified person responsible for pharmacovigilance (QPPV) and to maintain a pharmacovigilance system master file (PSMF), accessible electronically within the UK.

To ensure alignment with UK QPPV requirements, companies should establish a UK national contact for pharmacovigilance and understand the detailed UK PSMF requirements regarding content and accessibility under updated MHRA pharmacovigilance guidance.

Strategic Implications of MHRA QPPV and PSMF Guidance

This MHRA QPPV and PSMF guidance solidifies the UK's commitment to patient safety and regulatory harmonisation post-Brexit, impacting marketing authorisation holders by requiring a more stringent approach to their pharmacovigilance oversight.

As a result, companies impacted by this should review and update their pharmacovigilance systems and documentation to comply with the MHRA QPPV and PSMF guidance, in order to ensure their QPPV and PSMF meet the specified criteria.

To manage regulatory reporting workflows seamlessly, organizations can utilize automated safety platforms like RAPTAR. Furthermore, exploring specialized Regulatory Strategy Services and broader PharSafer Services helps teams navigate evolving UK regulatory expectations effectively.

For further assistance in aligning with these requirements, or for any queries regarding your Pharmacovigilance Services, please contact PharSafer’s experts today—where we are ready to support you in navigating these updates and ensure enhanced levels of compliance.